Free Trial

Zynex Q3 2023 Earnings Report

Zynex logo
$8.17 -0.19 (-2.27%)
As of 02:17 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Zynex EPS Results

Actual EPS
$0.10
Consensus EPS
$0.10
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Zynex Revenue Results

Actual Revenue
$49.92 million
Expected Revenue
$49.50 million
Beat/Miss
Beat by +$420.00 thousand
YoY Revenue Growth
N/A

Zynex Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Zynex Earnings Headlines

Zynex (ZYXI) Gets a Buy from RBC Capital
These guys expect TSLA to reach $700 a share by August
Twitter lit up this morning after someone put a $4,000,000 bet on TSLA. These guys lit up the $700 strike calls for August 2025… This is odd, considering Tesla only trades for around $350 a share today… In other words, these guys are betting that Tesla’s stock will surge by 100% over the months ahead. In my opinion, that’s an incredibly risky bet. A lot can happen between now and then… Besides, there is a better way to target that same 100% return without waiting until August.
See More Zynex Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Zynex? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zynex and other key companies, straight to your email.

About Zynex

Zynex (NASDAQ:ZYXI), together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and braces for rehabilitation support. Further, it offers Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring and intravascular volume monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.

View Zynex Profile

More Earnings Resources from MarketBeat